SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Closure Medical (CLSR) fomerly Tri-Point Medical (TPMC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Saban Kurucay who wrote (41)9/21/1997 7:05:00 PM
From: JYatsu   of 184
 
Just want to interject that CLSR has a 5 yr exclusive co-marketing agreement with J&J. Though I agree it is overpriced based on current earnings, once FDA approval is granted CLSR should see increase in revenue. Though most people see the skin closure product for use in emergency rooms, its more practical usage will be in esthetic surgery ie plastic surgery. I see J&J only protecting its suture market from encroachment. Should the product be a success, & I expect it will given the experience of Canadian physicians, CLSR would probably be acquired by J&J. Just my .02 worth JYatsu
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News